SigTuple Technologies is an Indian AI-powered medical diagnostics company based in Bengaluru that combines artificial intelligence, robotics, microfluidics, and cloud computing to automate the manual review of visual medical data. Its flagship product Shonit is an AI-driven peripheral blood smear analysis solution that uses a smart microscope to capture images of blood smear slides and sends them to SigTuple's proprietary AI-powered cloud platform, Manthana, which performs image analytics and deep learning to generate detailed blood reports. The company develops smart screening solutions for hematology, urinalysis, cervical cytology, and ophthalmology, enabling tele-diagnostics for laboratories and hospitals.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2015
Employees
51–200
Total Funding
$52.3M
5 rounds
Total raised $52.3M across 5 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series C (extended, second close)
Date
2024
Amount
$4M
Valuation
—
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| 2024 | Series C (extended, second close) | $4M | — | SIDBI Venture Capital |
| March 2023 | Series C (extended) | $4.5M | — | Existing investors |
| 2019 | Series C (initial) | $19M | — | Trusted Insight |
Tathagato Rai Dastidar
Co-Founder & CEO
Rohit Kumar Pandey
Co-Founder (former)
Apurv Anand
Co-Founder (former)
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Scopio Labs
Tel Aviv-based digital cell morphology and hematology company providing full-field imaging platforms and AI-powered applications for peripheral blood smear analysis.
Sight Diagnostics
Israeli medical device company developing AI-powered hematology analyzers (OLO) for complete blood count testing using machine vision.
CellaVision
Swedish-listed company providing digital cell morphology systems for hematology laboratories, the long-established incumbent in automated blood cell imaging.
Techcyte
US-based AI software platform for anatomic and clinical pathology, with applications across hematology, cytology, parasitology, and digital microscopy.
PathAI
US-based AI-powered pathology company providing diagnostic algorithms and digital pathology infrastructure for pharma and clinical labs.
Paige
US-based AI pathology company developing FDA-cleared computational pathology applications for cancer diagnostics.
No. SigTuple is a private company and does not have a public stock ticker or trade on a public stock exchange. Its shares are generally held by founders, employees, investors, and other private shareholders. Buyers and sellers may be able to transact in SigTuple shares through private secondary transactions, but any transaction depends on share availability, buyer and seller agreement, transfer restrictions, company approval rights, and any applicable right of first refusal. There is no guarantee that SigTuple will complete an IPO or other liquidity event.
Yes, it is sometimes possible to buy SigTuple shares pre-IPO through private secondary transactions. This depends on finding a willing seller, company approval, and satisfying any transfer restrictions or rights of first refusal.
Buyers interested in buying SigTuple shares on the secondary market typically do so through SetterVC and other secondary-market platforms, subject to eligibility requirements, share availability, transfer restrictions, and issuer approval. Buyers may need to satisfy sophistication, accreditation, institutional, platform, regulatory, or other eligibility requirements before participating. Once eligible, buyers may be able to view listings, make bids, and work with a licensed broker through the transaction process. Buyers should ensure they have appropriate legal and financial advisors guiding them before completing any transaction.
SigTuple's latest disclosed funding round was a Series C (extended, second close) round in 2024. The round raised approximately $4M, with SIDBI Venture Capital listed as disclosed lead or major investors. Primary funding rounds are different from secondary transactions: in a primary round, capital goes to the company, while in a secondary transaction, investors buy existing shares from current shareholders. Funding-round data reflects publicly reported or collected information and may be incomplete.
SigTuple has raised approximately $52.3M in disclosed funding across 5 rounds. These figures reflect primary capital raised by the company and do not include every possible secondary transaction, undisclosed round, debt facility, or private transfer. Reported funding totals can change as new rounds are announced or older round details are corrected. Eligible users can use SetterVC to track SigTuple's funding history alongside private-market activity where available.
SigTuple's disclosed investors include SIDBI Venture Capital, Existing investors, Trusted Insight, Accel Partners and IDG Ventures. Investor lists are based on public reporting, company announcements, and collected funding-round data, and may be incomplete. Participation in a prior funding round does not mean those investors are currently buying or selling shares. On SetterVC, eligible users can review SigTuple's funding history, valuation history, and private-market activity alongside other venture-backed companies.
SigTuple's most-cited competitors include Scopio Labs, Sight Diagnostics, CellaVision, Techcyte, PathAI and Paige. Investors often compare these companies by sector, product focus, valuation, funding raised, growth signals, investor base, and private-market activity.
Secondary-market demand for SigTuple shares can be affected by company performance, revenue growth, profitability, funding history, valuation, investor interest, sector momentum, public-market conditions, expected timing of a liquidity event, and the availability of shares for sale. Demand can also be affected by transfer restrictions, company approval rights, right of first refusal processes, limited information, and the price expectations of buyers and sellers. Strong demand does not guarantee strong pricing, liquidity, or investment returns. Weak demand does not necessarily reflect the company's long-term prospects. Demand signals should not be treated as a recommendation or prediction of investment performance. Buyers and sellers should treat demand signals as informational and conduct their own diligence before transacting.
Sellers often rely on intermediaries and platforms, such as SetterVC and other secondary-market platforms, to identify potential buyers. The exact process varies by company and transaction, but sellers often begin by confirming their ownership, desired price, transferability, and any company approval or notice requirements. If the seller agrees with a buyer on acceptable price and terms, the company may need to be notified through a share transfer notice or similar process. If a right of first refusal, company approval right, or other transfer restriction applies, the seller may need to wait until that process is completed. The parties may then execute a purchase and sale agreement, complete required transfer documentation, and close if all required conditions are satisfied. Sellers should always seek proper legal and financial advice before completing the transaction.
Yes, current and former SigTuple employees, early investors, and other existing shareholders may be able to sell vested shares before an IPO through a private secondary sale. This is not automatic; it depends on whether the shareholder has transferable shares, whether there is buyer demand, and whether the company's governing documents permit the transfer. Many companies require prior notice, company approval, or a right of first refusal before shares can be sold. Sellers should also seek proper legal and financial advice before proceeding.
A SigTuple secondary transaction usually involves an existing shareholder selling shares to a buyer before a public listing. The buyer and seller typically agree on price, number of shares, share class, and closing conditions. The seller may then need to notify SigTuple through a share transfer notice or similar process. If SigTuple or existing investors have approval rights, transfer restrictions, or a right of first refusal, those steps may need to be completed before the transfer can close. The parties typically enter into a purchase and sale agreement, complete any required transfer documentation, and close only if the necessary conditions are satisfied. Timing and certainty can vary by company and transaction.
In most private secondary transactions, parties commonly use a purchase and sale agreement that outlines price, terms, and conditions. They may also use share transfer documentation, often a stock transfer notice, share transfer notice, transfer instruction, or similar document, along with any required company approval or right of first refusal materials. Proof of ownership, such as a cap table entry, share certificate, brokerage statement, issuer confirmation, or administrator confirmation, may also be important. Buyers often request recent company financials, but private companies may limit disclosure. Since every deal varies, buyers and sellers should consult legal and financial advisors to understand which documents are needed.
Buying SigTuple shares pre-IPO is risky. Shares are illiquid, no IPO or liquidity event is guaranteed, valuations can change, transfers may require company approval, and private companies may provide limited financial disclosure. Be prepared for total loss. SetterVC and Setter Capital do not provide due diligence, legal, tax, accounting, valuation, or investment advice. Buyers must conduct their own due diligence, verify information, and seek independent legal and investment advice before proceeding.
Private secondary shares are typically illiquid. Unlike public stocks, there is no active public market, so selling them can be difficult and time-consuming. Sales depend on finding a willing buyer and often require company approval. Investors should be prepared to hold the shares for an extended period, with no guarantee of a future sale. Always assess your need for liquidity before investing.
SetterVC and Setter Capital do not provide due diligence, legal, tax, accounting, valuation, or investment advice. Buyers must conduct their own due diligence, including verifying ownership, transferability, legal structure, company approval, and assessing the company's prospects. SetterVC and Setter Capital do not provide advice on whether an investment is good, what price to pay, or what the best bid or ask is. SetterVC and Setter Capital may share documents in some circumstances, but it does not guarantee their accuracy or completeness. Due diligence is essential. Seek legal and investment advice as needed.
Before buying SigTuple shares, a buyer should try to review the share class, price per share, implied valuation, transfer restrictions, ROFR process, company approval rights, seller ownership evidence, recent financing or tender-offer information, available financial information, information rights, resale restrictions, tax considerations, and expected liquidity paths. Not all information may be available for a private company. Buyers should confirm available diligence, process details, and information needs with their own legal, tax, and investment advisers.
SPVs carry risks. Examples include the need to confirm the company allows SPV-based transfers, verify that the SPV truly owns the shares or interests it claims to own, and ensure it has not sold more interests than it holds. Due diligence is essential. Seek legal and investment advice as needed.
Forward contracts carry risks. Examples include the seller refusing to transfer the shares at the future date, even if the seller owns them, the seller going bankrupt with creditors claiming the shares, or the seller committing the same shares to multiple parties. Due diligence is essential. Seek legal and investment advice as needed.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.